Insight Molecular Diagnostics Inc. (IMDX)
(Delayed Data from NSDQ)
$2.56 USD
+0.04 (1.59%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $2.55 -0.01 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Insight Molecular Diagnostics Inc.'s return on equity, or ROE, is -215.59% compared to the ROE of the Medical Info Systems industry of -42.68%. While this shows that IMDX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
IMDX 2.56 +0.04(1.59%)
Will IMDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMDX
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
IMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMDX
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft ...
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant ...
12 Health Care Stocks Moving In Friday's After-Market Session
Insight Molecular Diagnostics (IMDX) Gets a Buy from Lake Street
Insight Molecular Diagnostics (IMDX) Makes Strides in Transplant Rejection Testing | IMDX Stock News